Cerebral/ Cortical Visual Impairment: Screening, Identification and Outcome Prediction in Neonates
Recruiting
Observational Study
Preterm Less Than 32wks With IVH, WMI/PVL
Late Preterm or Term (37-42wks) With Neonatal Encephalopathy Treated With Hypothermia for HIE
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 31 Weeks – 42 Weeks
- Sex
- Any
- Study type
- Observational
- Participants needed
- 60 (estimated)
- Sponsor
- Brigham and Women's Hospital · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Cerebral/Cortical Visual Impairment (CVI) is the leading cause of childhood visual impairment in the United States and other industrialized countries. CVI is a brain-based visual disorder in which visual acuity or visual fields are reduced despite a normal eye examination or greater-than-expected visual impairment relative to ocular pathology. CVI is increasingly recognized in children with neurol…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Preterm infants born \< 32 weeks gestational age with any of the following:
* Germinal matrix/intraventricular hemorrhage (IVH)
* White matter injury (WMI), including periventricular leukomalacia (PVL)
* Late preterm infants (born 34-36 weeks gestation) or term infants (born 3…